Peregrine Pharmaceuticals Inc (NASDAQ:PPHM)
| 1.54 Data as of May 17 |  +0.03 / +1.99%Today’s Change | 0.42 Today|||52-Week Range 5.50 | +16.67% Year-to-Date |
Latest PPHM News | Press Releases
| Osiris Loss In-Line with Expectations - Analyst Blog May 08 / Zacks.com |
Today’s Trading
| Previous close | 1.51 |
| Today’s open | 1.56 |
| Day’s range | -- - -- |
| Volume | 1,342,125 |
| Average volume (3 months) | 2,310,642 |
| Market cap | $211.2M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | +10.71% |
| Earnings growth (this year) | +53.33% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +12.90% |
| P/E ratio | NM |
| Price/Sales | 2.58 |
| Price/Book | 16.47 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| STSIStar Scientific Inc | -0.04 | -3.03% |
| --Genufood Energy Enzy... | 0.00 | 0.00% |
| GALEGalena Biopharma Inc | -0.07 | -2.80% |
| PGNXProgenics Pharmaceut... | +0.18 | +4.36% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Next reporting date | July 15, 2013 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $15.2M |
| Annual profit (last year) | -$42.1M |
| Net profit margin | -276.50% |
Profile
Sector Health Technology |
Industry Medical Specialties |
President, Chief Executive Officer & Director Steven W. King |
Chief Financial Officer Paul J. Lytle, CPA |
Corporate headquarters Tustin, California |
Forecasts
